CooperVision revenues flat in Q3 FY2026 amid US inventory reduction; CooperCompanies retains CooperSurgical

CooperVision (CVI) reported little change in revenue for the third quarter of its fiscal year 2026. This stability occurred despite a reduction in US channel inventory, which is expected to negatively impact results in the final quarter of the year. Separately, CooperCompanies, the medical device parent company encompassing both CVI and CooperSurgical, retained CooperSurgical. The source provides limited detail on specific financial figures or the strategic rationale behind the retention decision beyond these core facts.